A detailed history of Center Book Partners LP transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Center Book Partners LP holds 3,429 shares of KRYS stock, worth $706,922. This represents 0.03% of its overall portfolio holdings.

Number of Shares
3,429
Previous 5,051 32.11%
Holding current value
$706,922
Previous $694,000 12.82%
% of portfolio
0.03%
Previous 0.04%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 07, 2025

SELL
$134.94 - $176.75 $218,872 - $286,688
-1,622 Reduced 32.11%
3,429 $605,000
Q2 2025

Aug 12, 2025

BUY
$123.36 - $181.0 $623,091 - $914,231
5,051 New
5,051 $694,000
Q4 2024

Feb 13, 2025

BUY
$156.64 - $199.61 $670,889 - $854,929
4,283 New
4,283 $670,000
Q4 2023

Feb 13, 2024

BUY
$96.0 - $128.29 $97,920 - $130,855
1,020 Added 23.64%
5,335 $661,000
Q3 2023

Nov 13, 2023

BUY
$108.51 - $130.22 $468,220 - $561,899
4,315 New
4,315 $500,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $5.29B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Center Book Partners LP Portfolio

Follow Center Book Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Center Book Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Center Book Partners LP with notifications on news.